Investments
29Portfolio Exits
10Funds
9Service Providers
1About HealthCare Ventures
HealthCare Ventures is a life science venture capital firm investing in pre-clinical or early clinical stage, project-focused companies with potential to transform patient care. They aim to identify high potential products within academia or pharmaceutical companies, develop them to clinical proof-of-concept within capital efficient, semi-virtual organizations, and generate superior returns through acquisitions by pharmaceutical and biotechnology companies.

Want to inform investors similar to HealthCare Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest HealthCare Ventures News
Jun 20, 2023
Share this article Share this article MONTREAL, June 20, 2023 /CNW/ - Finchley Healthcare Ventures is pleased to announce the nomination of Pierre Beauparlant, Ph.D. as Executive Managing Director. This new life science fund belongs to the Goodman family, which owns Pharmascience, a generic pharmaceutical company, also offering single-source specialty products through its Pendopharm division and bioanalytical services through its Royalmount Laboratories division. With over 25 years of experience in the pharmaceutical industry, Pierre brings a wealth of knowledge and expertise to the organization. Prior to joining Finchley Healthcare Ventures, Pierre has held leadership positions at Sanderling Ventures, Novartis Pharmaceuticals, and several development-stage biopharmaceutical companies. His diverse background has equipped him with a deep understanding of the entire drug development process, from discovery to commercialization. Throughout his career, Pierre has demonstrated exceptional skills in the creation, financing, and management of early-stage companies with a mission to develop new therapies. His strategic insights and business acumen have played a pivotal role in advancing numerous innovative projects and bringing them to market. We believe that with his extensive experience and track record of success, Pierre will be instrumental in guiding our venture capital fund towards identifying and supporting ground-breaking companies and investment funds in the pharmaceutical sector. His leadership will further strengthen our commitment to fostering innovation and driving the growth of companies with the potential to transform patient care. We extend a warm welcome to Pierre and look forward to the valuable contributions he will make in advancing our mission to support the development and commercialization of new therapies that improve the lives of patients worldwide through our financial investment and by making Pharmascience quality bioanalytical and manufacturing expertise available to Finchley Healthcare Ventures portfolio companies. About Finchley Healthcare Ventures Finchley Healthcare Ventures (FHCV) is a Canadian venture capital fund founded in 2022 specializing in investments within the rapidly evolving landscape of life sciences. With a passion for advancing healthcare and a keen focus on fostering innovation, FHCV is dedicated to supporting companies developing new and transformative medicines, as well as investing in other venture capital funds operating in the life sciences sector. FHCV invests in companies that are pushing the boundaries of medical research and development, with a particular emphasis on those developing novel therapies. FHCV seeks out opportunities where breakthrough technologies and transformative ideas have the potential to address significant unmet medical needs and revolutionize patient care. The organization also invests in venture capital funds specializing in life sciences and seeks to leverage their expertise and network to access a diverse range of investment opportunities. This approach allows FHCV to diversify its portfolio while also benefiting from the specialized knowledge and due diligence capabilities of these investment partners. About Pharmascience Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2023, the company was recognized for its investments by being selected as one of Canada's Top Employers for Young People, as part of the Canada's Top 100 Employers project. Also in 2023, Pharmascience was certified as a Great Place to Work for the second year running. SOURCE Finchley
HealthCare Ventures Investments
29 Investments
HealthCare Ventures has made 29 investments. Their latest investment was in CathVision as part of their Series C on August 8, 2022.

HealthCare Ventures Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/17/2022 | Series C | CathVision | $7.2M | Yes | HealthCare Ventures, Nordic Secondary Fund, Undisclosed Investors, and Vækstfonden | 2 |
6/21/2022 | Series B | MyOme | $23M | Yes | 2 | |
7/13/2020 | Series B - III | Paige | $20M | Yes | 8 | |
9/12/2011 | Series A | |||||
8/2/2011 | Series A |
Date | 8/17/2022 | 6/21/2022 | 7/13/2020 | 9/12/2011 | 8/2/2011 |
---|---|---|---|---|---|
Round | Series C | Series B | Series B - III | Series A | Series A |
Company | CathVision | MyOme | Paige | ||
Amount | $7.2M | $23M | $20M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | HealthCare Ventures, Nordic Secondary Fund, Undisclosed Investors, and Vækstfonden | ||||
Sources | 2 | 2 | 8 |
HealthCare Ventures Portfolio Exits
10 Portfolio Exits
HealthCare Ventures has 10 portfolio exits. Their latest portfolio exit was Tensha Therapeutics on January 11, 2016.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/11/2016 | Acquired | 3 | |||
2/7/2008 | Acquired | Undisclosed Investors | |||
9/8/2000 | Acquired | ||||
Date | 1/11/2016 | 2/7/2008 | 9/8/2000 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Undisclosed Investors | ||||
Sources | 3 |
HealthCare Ventures Fund History
9 Fund Histories
HealthCare Ventures has 9 funds, including HealthCare Ventures VIII LP.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
8/18/2005 | HealthCare Ventures VIII LP | Early-Stage Venture Capital | Closed | $379M | 1 |
11/19/2002 | HealthCare Ventures VII LP | ||||
12/21/2000 | HealthCare Ventures VI LP | ||||
12/31/1997 | HealthCare Ventures V LP | ||||
4/30/1993 | HealthCare Ventures III & IV LP |
Closing Date | 8/18/2005 | 11/19/2002 | 12/21/2000 | 12/31/1997 | 4/30/1993 |
---|---|---|---|---|---|
Fund | HealthCare Ventures VIII LP | HealthCare Ventures VII LP | HealthCare Ventures VI LP | HealthCare Ventures V LP | HealthCare Ventures III & IV LP |
Fund Type | Early-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $379M | ||||
Sources | 1 |
HealthCare Ventures Service Providers
1 Service Provider
HealthCare Ventures has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Counsel |
Service Provider | |
---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type |
Partnership data by VentureSource
HealthCare Ventures Team
6 Team Members
HealthCare Ventures has 6 team members, including current Managing Director, Douglas E. Onsi.
Name | Work History | Title | Status |
---|---|---|---|
Douglas E. Onsi | Managing Director | Current | |
Name | Douglas E. Onsi | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Managing Director | ||||
Status | Current |
Compare HealthCare Ventures to Competitors
Informed Medical is an interactive medical information services provider that enables biopharmaceutical companies to market directly to physicians and patients.

Sai Life Sciences offers their clients a wide range of integrated drug discovery, development and formulation services, with core expertise founded in synthetic, medicinal and process chemistry and further augmented by a suite of preclinical support services including DMPK, toxicology and formulation that are continually expanding to meet clients' needs.
Ardent Health Services, previously known as Behavioral Healthcare, invests in people, technology, facilities, and communities, producing high-quality care and extraordinary results. Ardent currently operates three health systems with a range of hospitals and employs multi-specialty physicians in multiple clinic locations across New Mexico, Oklahoma, and Texas. The company was founded in 1993 and is based in Nashville, Tennessee.
ElexoPharm is a German biotech company, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University. ElexoPharm is focused on the preclinical discovery and optimization of drugs for human diseases, which are currently not or insufficiently treatable with existing drugs.
Veratect offers services that aim to offer the early detection, 24/7 tracking and actionable alert generation of emerging threats (pandemics) worldwide. The company offers the Foreshadow and VeraSight. Per the company, Veratect provides timely and actionable information that supports informed decisions across a broad range of public and private institutions. By identifying emerging risks early, Veratect contends that actions can be taken that save human life, enable loss control, preserve business processes, safeguard supply chain operations and facilities, better manage financial reporting and insurance coverage, and mitigate potential class action lawsuits due to negligence in responding to threats in a timely manner.

Blaze Systems is a provider of total LIMS software solutions for the laboratory marketplace.